Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
JAMA Netw Open ; 6(10): e2339723, 2023 10 02.
Artigo em Inglês | MEDLINE | ID: mdl-37878309

RESUMO

Importance: Prior studies suggested that metformin may be associated with reduced dementia incidence, but associations may be confounded by disease severity and prescribing trends. Cessation of metformin therapy in people with diabetes typically occurs due to signs of kidney dysfunction but sometimes is due to less serious adverse effects associated with metformin. Objective: To investigate the association of terminating metformin treatment for reasons unrelated to kidney dysfunction with dementia incidence. Design, Setting, and Participants: This cohort study was conducted at Kaiser Permanente Northern California, a large integrated health care delivery system, among a cohort of metformin users born prior to 1955 without history of diagnosed kidney disease at metformin initiation. Dementia follow-up began with the implementation of electronic health records in 1996 and continued to 2020. Data were analyzed from November 2021 through September 2023. Exposures: A total of 12 220 early terminators, individuals who stopped metformin with normal estimated glomerular filtration rate (eGFR), were compared with routine metformin users, who had not yet terminated metformin treatment or had terminated (with or without restarting) after their first abnormal eGFR measurement. Early terminators were matched with routine users of the same age and gender who had diabetes for the same duration. Main outcomes and measures: The outcome of interest was all-cause incident dementia. Follow-up for early terminators and their matched routine users was started at age of termination for the early terminator. Survival models adjusted for sociodemographic characteristics and comorbidities at the time of metformin termination (or matched age). Mediation models with HbA1c level and insulin usage 1 and 5 years after termination tested whether changes in blood glucose or insulin usage explained associations between early termination of metformin and dementia incidence. Results: The final analytic sample consisted of 12 220 early terminators (5640 women [46.2%]; mean [SD] age at start of first metformin prescription, 59.4 [9.0] years) and 29 126 routine users (13 582 women [46.6%]; mean [SD] age at start of first metformin prescription, 61.1 [8.9] years). Early terminators had 1.21 times the hazard of dementia diagnosis compared with routine users (hazard ratio, 1.21; 95% CI, 1.12 to 1.30). In mediation analysis, contributions to this association by changes in HbA1c level or insulin use ranged from no contribution (0.00 years; 95% CI, -0.02 to 0.02 years) for insulin use at 5 years after termination to 0.07 years (95% CI, 0.02 to 0.13 years) for HbA1c level at 1 year after termination, suggesting that the association was largely independent of changes in HbA1c level and insulin usage. Conclusions and Relevance: In this study, terminating metformin treatment was associated with increased dementia incidence. This finding may have important implications for clinical treatment of adults with diabetes and provides additional evidence that metformin is associated with reduced dementia risk.


Assuntos
Demência , Diabetes Mellitus , Adulto , Humanos , Feminino , Criança , Estudos de Coortes , Hemoglobinas Glicadas , Incidência , Insulina , Insulina Regular Humana , Morte , Demência/epidemiologia
2.
Neurology ; 101(21): e2172-e2184, 2023 Nov 21.
Artigo em Inglês | MEDLINE | ID: mdl-37793911

RESUMO

BACKGROUND AND OBJECTIVES: The associations of high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) with dementia risk in later life may be complex, and few studies have sufficient data to model nonlinearities or adequately adjust for statin use. We evaluated the observational associations of HDL-C and LDL-C with incident dementia in a large and well-characterized cohort with linked survey and electronic health record (EHR) data. METHODS: Kaiser Permanente Northern California health plan members aged 55 years and older who completed a health behavior survey between 2002 and 2007, had no history of dementia before the survey, and had laboratory measurements of cholesterol within 2 years after survey completion were followed up through December 2020 for incident dementia (Alzheimer disease-related dementia [ADRD]; Alzheimer disease, vascular dementia, and/or nonspecific dementia) based on ICD-9 or ICD-10 codes in EHRs. We used Cox models for incident dementia with follow-up time beginning 2 years postsurvey (after cholesterol measurement) and censoring at end of membership, death, or end of study period. We evaluated nonlinearities using B-splines, adjusted for demographic, clinical, and survey confounders, and tested for effect modification by baseline age or prior statin use. RESULTS: A total of 184,367 participants [mean age at survey = 69.5 years, mean HDL-C = 53.7 mg/dL (SD = 15.0), mean LDL-C = 108 mg/dL (SD = 30.6)] were included. Higher and lower HDL-C values were associated with elevated ADRD risk compared with the middle quantile: HDL-C in the lowest quintile was associated with an HR of 1.07 (95% CI 1.03-1.11), and HDL-C in the highest quintile was associated with an HR of 1.15 (95% CI 1.11-1.20). LDL-C was not associated with dementia risk overall, but statin use qualitatively modified the association. Higher LDL-C was associated with a slightly greater risk of ADRD for statin users (53% of the sample, HR per 10 mg/dL increase = 1.01, 95% CI 1.01-1.02) and a lower risk for nonusers (HR per 10 mg/dL increase = 0.98; 95% CI 0.97-0.99). There was evidence for effect modification by age with linear HDL-C (p = 0.003) but not LDL-C (p = 0.59). DISCUSSION: Both low and high levels of HDL-C were associated with elevated dementia risk. The association between LDL-C and dementia risk was modest.


Assuntos
Doença de Alzheimer , Inibidores de Hidroximetilglutaril-CoA Redutases , Humanos , Idoso , HDL-Colesterol , LDL-Colesterol , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Doença de Alzheimer/epidemiologia , Seguimentos , Fatores de Risco , Colesterol , Atenção à Saúde
3.
Psychopharmacology (Berl) ; 239(5): 1289-1309, 2022 May.
Artigo em Inglês | MEDLINE | ID: mdl-34165606

RESUMO

RATIONALE: Tolerance to cannabinoids could limit their therapeutic potential. Male mice expressing a desensitization-resistant form (S426A/S430A) of the type-1 cannabinoid receptor (CB1R) show delayed tolerance to delta-9-tetrahydrocannabinol (∆9-THC) but not CP55,940. With more women than men using medical cannabis for pain relief, it is essential to understand sex differences in cannabinoid antinociception, hypothermia, and resultant tolerance. OBJECTIVE: Our objective was to determine whether female mice rely on the same molecular mechanisms for tolerance to the antinociceptive and/or hypothermic effects of cannabinoids that we have previously reported in males. We determined whether the S426A/S430A mutation differentially disrupts antinociceptive and/or hypothermic tolerance to CP55,940 and/or Δ9-THC in male and female S426A/S430A mutant and wild-type littermates. RESULTS: The S426A/S430A mutation conferred an enhanced antinociceptive response for ∆9-THC and CP55,940 in both male and female mice. While the S426A/S430A mutation conferred partial resistance to ∆9-THC tolerance in male mice, disruption of CB1R desensitization had no effect on tolerance to ∆9-THC in female mice. The mutation did not alter tolerance to the hypothermic effects of ∆9-THC or CP55,940 in either sex. Interestingly, female mice were markedly less sensitive to the antinociceptive effects of 30 mg/kg ∆9-THC and 0.3 mg/kg CP55,940 compared with male mice. CONCLUSIONS: Our results suggest that disruption of the GRK/ßarrestin2 pathway of desensitization alters tolerance to Δ9-THC but not CP55,940 in male but not female mice. As tolerance to Δ9-THC appears to develop differently in males and females, sex should be considered when assessing the therapeutic potential and dependence liability of cannabinoids.


Assuntos
Canabinoides , Hipotermia , Analgésicos/farmacologia , Animais , Agonistas de Receptores de Canabinoides/farmacologia , Canabinoides/farmacologia , Cicloexanóis , Dronabinol/farmacologia , Feminino , Humanos , Masculino , Camundongos
4.
Open J Vet Med ; 3(1): 1-5, 2013 Mar 21.
Artigo em Inglês | MEDLINE | ID: mdl-25938006

RESUMO

Obesity has not been linked to causing intervertebral disc degeneration, but has been shown to influence time to ambulation, a strong long-term prognostic indicator in dogs with intervertebral disc disease. However, monitoring obesity to date is imprecise and subjective in the clinical setting. Having an objective formula based on morphometric measurements would potentially be more precise to track our patients' weights. Dogs have been shown to gain weight along their lumbar spine more rapidly than other areas. Varying body conformations make extrapolation from nonchondrodystrophic dogs to Dachshunds difficult. This study aimed to establish the region of fat accumulation along the thoracolumbar spine in Dachshunds. Retrospective computed tomographic (CT) analysis was performed on healthy Dachshunds that presented for intervertebral disc disease (IVDD). Fat area measured at L3 and L5 using attenuation ranges -135/-105 Hounsfield units (HU) was the most dependent on body weight (p = 0.05). There appeared to be no difference between subcutaneous, visceral or total percent body fat with weight agreement. T13, L3 and L5 all had linear relationships with patient weight and will likely be helpful for body mass index (BMI) formula creation (p < 0.01). This study indicates that any consistent location between L3 and L5 will give an accurate representation of the abdominal circumference and most obese area of the Dachshund with the umbilicus used as a landmark.

5.
Vet Clin North Am Small Anim Pract ; 39(4): 761-81, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19531400

RESUMO

When performing an abdominal ultrasound examination in dogs, a right lateral intercostal approach often is indicated. This approach allows for a complete examination of the abdomen, especially in large deep-chested dogs, dogs with microhepatica, or dogs with a large volume of intestinal gas or peritoneal effusion. The right lateral intercostal approach provides an acoustic window for the evaluation of the right side of the liver, porta hepatis, right limb and body of the pancreas, duodenum, right kidney, right adrenal gland, and hepatic lymph nodes.


Assuntos
Abdome/diagnóstico por imagem , Doenças do Cão/diagnóstico por imagem , Medicina Veterinária/métodos , Glândulas Suprarrenais/diagnóstico por imagem , Animais , Cães , Rim/diagnóstico por imagem , Fígado/irrigação sanguínea , Fígado/diagnóstico por imagem , Cirrose Hepática/diagnóstico por imagem , Cirrose Hepática/veterinária , Pâncreas/diagnóstico por imagem , Veia Porta/anormalidades , Veia Porta/diagnóstico por imagem , Ultrassonografia/métodos , Ultrassonografia/veterinária
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...